Is ORYZF or QYLD a better dividend investment in 2026?

ORYZF currently yields 59.88% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: ORYZF offers higher current income.

What is the dividend yield difference between ORYZF and QYLD?

ORYZF has a forward dividend yield of 59.88% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 47.96 percentage points.

Home › Compare › ORYZF vs QYLD

ORYZF vs QYLD: Dividend Comparison 2026

ORYZF yields 59.88% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ORYZF wins by $622.3K in total portfolio value

INVESTMENT

TIME HORIZON10 years

ORYZF

● Live price

59.88%

Share price

$3.34

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$647.7K

Annual income

$151,154.17

Full ORYZF calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — ORYZF vs QYLD

📍 ORYZF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ORYZF	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ORYZF + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ORYZF pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORYZF

Annual income on $10K today (after 15% tax)

$5,089.82/yr

After 10yr DRIP, annual income (after tax)

$128,481.04/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, ORYZF beats the other by $123,670.63/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORYZF + QYLD for your $10,000?

ORYZF: 50%QYLD: 50%

100% QYLD50/50100% ORYZF

Portfolio after 10yr

$336.6K

Annual income

$78,406.75/yr

Blended yield

23.30%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORYZF buys

QYLD buys

No recent congressional trades found for ORYZF or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricORYZFQYLD

Forward yield	59.88% ✓	11.92%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$647.7K ✓	$25.4K
Annual income after 10y	$151,154.17 ✓	$5,659.31
Total dividends collected	$536.9K ✓	$27.1K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: ORYZF vs QYLD ($10,000, DRIP)

Year	ORYZF Portfolio	ORYZF Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$16,688	$5,988.02	$10,352	$1,192.36	+$6.3K → ORYZF
2	$27,195	$9,339.09	$10,830	$1,347.57	+$16.4K → ORYZF
3	$43,323	$14,223.60	$11,460	$1,539.07	+$31.9K → ORYZF
4	$67,531	$21,176.11	$12,275	$1,777.84	+$55.3K → ORYZF
5	$103,108	$30,849.85	$13,323	$2,078.95	+$89.8K → ORYZF
6	$154,347	$44,020.82	$14,667	$2,463.34	+$139.7K → ORYZF
7	$226,736	$61,585.45	$16,396	$2,960.57	+$210.3K → ORYZF
8	$327,159	$84,550.92	$18,631	$3,612.97	+$308.5K → ORYZF
9	$464,078	$114,017.62	$21,548	$4,482.15	+$442.5K → ORYZF
10	$647,717	$151,154.17	$25,398	$5,659.31	+$622.3K → ORYZF

ORYZF vs QYLD: Complete Analysis 2026

ORYZF — Stock

Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

Full ORYZF Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this ORYZF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORYZF vs SCHD ORYZF vs JEPI ORYZF vs O ORYZF vs KO ORYZF vs MAIN ORYZF vs XYLD ORYZF vs JEPQ ORYZF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.